News

The company claims that AstraZeneca and its wholly-owned subsidiary, Tika have disregarded their obligations under the three agreement with Verus signed in 2007. Under the terms of the

As per report, medical device spending rose only slightly as a percent of NHE-growing from 5.4% in 1989 to 6.2% in 2006- a 0.8 percentage point increase over

The VX-770 registration program will consist of three clinical trials, including a primary 48 week phase III trial that is currently open to enroll patients aged 12 years

Sciele will share development costs for PSD502 for non-US territories and pay royalties to Plethora on non-US revenues. Ed Schutter, President and COO, Sciele Pharma, said: “we are

“As part of a continuing effort to be the imaging provider in the New England market, Shields senior management developed an optimization strategy for the operation of all

Originally, 11% was planned. The current sales and cost projection until the end of fiscal year 2009 is the basis for this change. Moreover, the management board with

Dr. Mel Spigelman, CEO of TB Alliance, said: “These partnerships show that the TB Alliance is aggressively increasing the depth and strength of its portfolio to ensure that

AFIRM has a special interest in using the most advanced regenerative medicine for its wounded soldiers and recognises Avita’s innovative treatment for burns and other skin injuries has

Sanofi will initiate the development process called passaging, which will yield a working seed for the vaccine. Passaging is the process to acclimate virus to grow in a